Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajco.14193 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nivolumab-Induced Lichenoid Eruption: A Case Report.
Cureus
June 2025
Dermatology, Hospital Garcia de Orta, Almada, PRT.
Immune checkpoint inhibitors, such as nivolumab, are associated with a broad spectrum of cutaneous immune-related adverse events, among which lichenoid eruptions are increasingly recognized. We describe a case of nivolumab-induced lichenoid eruption in a patient with metastatic desmoplastic melanoma. Five months after treatment initiation, the patient developed pruritic violaceous papules and plaques, with histopathology revealing lichenoid interface dermatitis.
View Article and Find Full Text PDFRapid-Onset Myositis and Myocarditis Following Dual Immune Checkpoint Inhibitor Therapy With Nivolumab and Ipilimumab for Gastric Adenocarcinoma: A Case Report.
Cureus
May 2025
Internal Medicine, Northeast Georgia Medical Center Gainesville, Gainesville, USA.
Immune checkpoint inhibitors (ICIs) have revolutionized oncology by improving survival outcomes with fewer side effects than traditional chemotherapy. However, ICIs are associated with immune-related adverse events (irAEs) affecting various organ systems, including rare neuromuscular complications such as myositis and myocarditis. This report presents a 70-year-old male with gastric adenocarcinoma, Lynch syndrome, and other comorbidities who developed severe myositis and myocarditis, confirmed by MRI and enzyme testing, 11 days after his first cycle of nivolumab and ipilimumab.
View Article and Find Full Text PDFA Case of Nivolumab-Related Myasthenia Gravis With Pretreatment Positive Anti-Acetylcholine Receptor Antibodies, and a Literature Review.
Asia Pac J Clin Oncol
May 2025
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Multiple Cutaneous Adverse Reactions Secondary to Nivolumab Therapy in an Elderly Male.
Cureus
March 2025
Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, IND.
Nivolumab is a human IgG4, PD-1 inhibitor that is approved for the treatment of advanced melanoma. We hereby report a patient of metastatic melanoma who developed multiple cutaneous side effects, including Sweet's syndrome, lichenoid eruption, and vitiligo-like depigmentation after initiation of the nivolumab therapy. He first started developing vitiligo-like depigmentation over the lips, which appeared after five months.
View Article and Find Full Text PDFA Case of Nivolumab-Induced Multiorgan Toxicity: Concurrent Myocarditis and Interstitial Pneumonia.
Cureus
March 2025
General Medicine, Faculty of Medicine, Oda Training Center of General Practice, Oda Municipal Hospital, Shimane University, Oda, JPN.
This is a rare case of nivolumab-induced multiorgan toxicity presenting as concurrent myocarditis and interstitial pneumonia in an 81-year-old patient with metastatic renal cell carcinoma. Immune checkpoint inhibitor (ICI)-associated myocarditis, a high-mortality immune-related adverse event (irAE), often presents with nonspecific symptoms, complicating early diagnosis, particularly when coexisting with other irAEs. In this case, the diagnosis was supported by elevated cardiac biomarkers, multimodal imaging findings (echocardiography, cardiac MRI, and coronary CT angiography), and electrocardiogram (ECG) abnormalities, including new-onset atrial fibrillation and right bundle branch block, indicative of myocardial involvement.
View Article and Find Full Text PDF